Christopher Ryan Sullivan - Mar 28, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Chief Financial Officer
Signature: /s/ Donald R. Reynolds, by Power of Attorney
Stock symbol: AVTX
Transactions as of: Mar 28, 2025
Transactions value $: -$61,631
Form type: 4
Date filed: 4/1/2025, 04:11 PM
Previous filing: Jan 30, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTX	Common Stock	Options Exercise		+24.2K	+403333.33%		24.2K	Mar 28, 2025	Direct	F1
transaction	AVTX	Common Stock	Tax liability	-$61.6K	-7.29K	-30.1%	$8.46	16.9K	Mar 28, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTX	Restricted Stock Units	Options Exercise	$0	-24.2K	-33.33%	$0.00	48.4K	Mar 28, 2025	Common Stock	24.2K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.